In a retrospective cohort study, Nemani et al assessed the association between diagnosis of schizophrenia spectrum disorders, mood disorders, and anxiety disorders with mortality among patients who were positive for COVID-19 in a large medical system in New York. Of 7,348 laboratory-confirmed COVID-19 patients, 1% of patients had a history of schizophrenia spectrum illness, 7.7% of patients had a history of a mood disorder, and 4.9% had a history of an anxiety disorder. The authors found that premorbid diagnosis with a schizophrenia spectrum disorder was associated with increased risk of mortality (aOR: 2.67). Mood disorders and anxiety disorders were not associated with mortality after adjustment for demographic and medical risk factors.